A5102722674- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Xenotransplantation and immune response
- Cancer Immunotherapy and Biomarkers
- Transplantation: Methods and Outcomes
- Cancer Genomics and Diagnostics
- Immune Cell Function and Interaction
University of Pennsylvania
2024
BC Cancer Agency
2017
Data Harbor (United States)
2015
Oncogenic "driver" mutations are theoretically attractive targets for the immunotherapy of lymphoid cancers, yet proportion that can be recognized by T cells remains poorly defined. To address this issue without any confounding effects patient's immune system, we assessed from 19 healthy donors recognition three common driver in lymphoma: MYD88L265P, EZH2Y641F, and EZH2Y641N. Donors collectively expressed 10 most prevalent HLA class I alleles, including HLA-A*02:01. Peripheral blood were...
Meeting abstracts A fundamental challenge in cancer genomics is to design effective, personalized treatments based on the mutational profiles of tumors. Pharmacological targeting numerous aberrant pathways found individual tumors remains exceedingly challenging, but T cell-based therapies